TY - JOUR
T1 - The clear cell sarcoma functional genomic landscape
AU - Panza, Emanuele
AU - Ozenberger, Benjamin B.
AU - Straessler, Krystal M.
AU - Barrott, Jared J.
AU - Li, Li
AU - Wang, Yanliang
AU - Xie, Mingchao
AU - Boulet, Anne
AU - Titen, Simon W.A.
AU - Mason, Clinton C.
AU - Lazar, Alexander J.
AU - Ding, Li
AU - Capecchi, Mario R.
AU - Jones, Kevin B.
N1 - Funding Information:
Brian Dalley from the High-Throughput Genomics core facility at the University of Utah assisted with transcriptome and genome sequencing, and Chris Stubben and Tim Parnell from the Bioin-formatics Shared Resource at the University of Utah with analysis. BioDiscovery provided software and analysis support for the OncoScan array hybridizations. All animal imaging was performed at the Preclinical Imaging Core Facility at the University of Utah. This work was supported by the Cure Childhood Cancer Foundation, the Pablove Foundation, and Sara’s Cure (to KBJ), as well as by NIH grant R01 MH093595 (to MRC) and the Halt Cancer at X Foundation (to SWAT). CCM was supported by the Pediatric Cancer Program, which is funded by the Intermountain Healthcare and Primary Children’s Hospital Foundations and the Department of Pediatrics at the University of Utah.
Publisher Copyright:
© 2021, American Society for Clinical Investigation.
PY - 2021/8
Y1 - 2021/8
N2 - Clear cell sarcoma (CCS) is a deadly malignancy affecting adolescents and young adults. It is characterized by reciprocal translocations resulting in expression of the chimeric EWSR1-ATF1 or EWSR1-CREB1 fusion proteins, driving sarcomagenesis. Besides these characteristics, CCS has remained genomically uncharacterized. Copy number analysis of human CCSs showed frequent amplifications of the MITF locus and chromosomes 7 and 8. Few alterations were shared with Ewing sarcoma or desmoplastic, small round cell tumors, which are other EWSR1-rearranged tumors. Exome sequencing in mouse tumors generated by expression of EWSR1-ATF1 from the Rosa26 locus demonstrated no other repeated pathogenic variants. Additionally, we generated a new CCS mouse by Cre-loxP–induced chromosomal translocation between Ewsr1 and Atf1, resulting in copy number loss of chromosome 6 and chromosome 15 instability, including amplification of a portion syntenic to human chromosome 8, surrounding Myc. Additional experiments in the Rosa26 conditional model demonstrated that Mitf or Myc can contribute to sarcomagenesis. Copy number observations in human tumors and genetic experiments in mice rendered, for the first time to our knowledge, a functional landscape of the CCS genome. These data advance efforts to understand the biology of CCS using innovative models that will eventually allow us to validate preclinical therapies necessary to achieve longer and better survival for young patients with this disease.
AB - Clear cell sarcoma (CCS) is a deadly malignancy affecting adolescents and young adults. It is characterized by reciprocal translocations resulting in expression of the chimeric EWSR1-ATF1 or EWSR1-CREB1 fusion proteins, driving sarcomagenesis. Besides these characteristics, CCS has remained genomically uncharacterized. Copy number analysis of human CCSs showed frequent amplifications of the MITF locus and chromosomes 7 and 8. Few alterations were shared with Ewing sarcoma or desmoplastic, small round cell tumors, which are other EWSR1-rearranged tumors. Exome sequencing in mouse tumors generated by expression of EWSR1-ATF1 from the Rosa26 locus demonstrated no other repeated pathogenic variants. Additionally, we generated a new CCS mouse by Cre-loxP–induced chromosomal translocation between Ewsr1 and Atf1, resulting in copy number loss of chromosome 6 and chromosome 15 instability, including amplification of a portion syntenic to human chromosome 8, surrounding Myc. Additional experiments in the Rosa26 conditional model demonstrated that Mitf or Myc can contribute to sarcomagenesis. Copy number observations in human tumors and genetic experiments in mice rendered, for the first time to our knowledge, a functional landscape of the CCS genome. These data advance efforts to understand the biology of CCS using innovative models that will eventually allow us to validate preclinical therapies necessary to achieve longer and better survival for young patients with this disease.
UR - http://www.scopus.com/inward/record.url?scp=85111832807&partnerID=8YFLogxK
U2 - 10.1172/JCI146301
DO - 10.1172/JCI146301
M3 - Article
C2 - 34156976
AN - SCOPUS:85111832807
SN - 0021-9738
VL - 131
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 15
M1 - 146301
ER -